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Abstract 
Globally, some 71 million people are chronically infected with hepatitis C virus (HCV). Marginalised 
populations, particularly people who inject drugs (PWID), have low testing, linkage-to-care and 
treatment rates for HCV. Several models of care (MoCs) and service delivery interventions have the 
potential to improve outcomes across the HCV cascade of care, but much of the relevant research 
was carried out when interferon-based treatment was the standard of care. Often it was not 
practical to scale up these earlier models and interventions because the clinical care needs of 
patients taking interferon-based regimens imposed too much of a financial and human resource 
burden on health systems. Despite the adoption of highly effective, all-oral direct-acting antiviral 
(DAA) therapies in recent years, approaches to HCV testing and treatment have evolved slowly and 
often remain rooted in earlier paradigms. The effectiveness of DAAs allows for simpler approaches 
and has encouraged countries where the drugs are widely available to set their sights on the 
ambitious World Health Organization (WHO) HCV elimination targets. Since a large proportion of 
chronically HCV-infected people are not currently accessing treatment, there is an urgent need to 
identify and implement existing simplified MoCs that speak to specific populations’ needs. This 
article aims to: 1) review the evidence on MoCs for HCV; and 2) distil the findings into 
recommendations for how stakeholders can simplify the path taken by chronically HCV-infected 
individuals from testing to cure and subsequent care and monitoring. 
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Introduction 
 
Viral hepatitis is a leading cause of mortality globally, with the hepatitis C virus (HCV) responsible for 
an estimated 350,000 deaths and 9.7 million disability-adjusted life years in 2016. [1] The World 
Health Organization (WHO) estimates that 80% of the people living with HCV have not been 
diagnosed. [2] Although HCV became a highly curable disease with the introduction of all-oral direct-
acting antiviral agents (DAAs) in 2013, most countries have been slow to provide unrestricted access 
to these life-saving drugs [3] [4] and thus decrease the disease’s spread [5] and reduce its 
prevalence. 
Given the gravity of the epidemic and the effectiveness of the cure, in 2016 WHO made the 
elimination of viral hepatitis as a public health threat by 2030 the overriding goal of its first global 
health sector strategy on viral hepatitis. [6] The strategy stresses equity and leaving no affected 
populations behind in its ambitious targets of achieving an 80% reduction in HCV incidence and a 
65% reduction in HCV mortality by 2030, as exemplified in its prevention target to increase the 
average number of sterile needles and syringes distributed to people who inject drugs (PWID) from 
20 to 300 annually. Today, the unsafe injection of illicit drugs is a main driver of the global HCV 
epidemic. [2,7] It is estimated that 15.6 million people injected drugs globally in 2015, [8] and that 
6.1 million of them were living with HCV. [9] Globally, if the risk of HCV transmission associated with 
sharing unsafe injecting equipment among people who currently inject drugs was removed, 43% of 
incident HCV cases would be prevented between 2018 and 2030. [10] 
Evidence shows that in many settings, a relatively modest increase in treatment rates can enable a 
country that already provides good access to DAAs to achieve the WHO strategy’s targets. A 2017 
study modelling the HCV epidemic in Switzerland concluded that an annual treatment uptake of 10% 
would eliminate the disease by 2030 in PWID. [11] A second study made comparable projections for 
other European countries, but also found that some countries would need to scale up opioid 
substitution therapy (OST) and needle and syringe exchange programmes (NSP) interventions to 
reduce chronic HCV prevalence. [12] Yet in most countries of the world, particularly low and middle-
income countries, access to DAAs and harm reduction services remains extremely limited, [13-15] 
and achieving the WHO targets will require major expansion of both forms of access. [16] That is 
because besides DAA therapy, which enables a sustained virologic response (SVR), the most effective 
form of HCV prevention for PWID is harm reduction, including opioid substitution therapy OST, NSPs, 
and supervised injecting centres.  
In reality, global elimination of HCV will require major increases in services for all affected 
populations along the entire cascade of care, including testing, linkage to care, retention in care, 
treatment, chronic care and prevention of primary infection and reinfection. 
 
The model of care (MoC): a tool for increasing treatment coverage 
In 2013, Bruggmann and Litwin found that, while HCV treatment had been successfully delivered to 
many people, through various multidisciplinary models, few treatment settings were adapted to the 
needs of PWID. [17] PWID who have been treated, e.g. with OST, are often those who are most 
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What is needed is a model of care (MoC) for each setting that specifically targets PWID and other 
marginalised high-burden populations, such as migrants or the homeless, while taking advantage of 
the characteristics of DAA therapy. 
In this review, we use MoC to signify a setting-specific framework that outlines how to provide the 
relevant services and interventions throughout the HCV cascade of care. An MoC should address 
four key questions: where to provide the services, what services to provide, who to provide them 
and how to integrate them. 
Box/Panel 1. Selection of new models of hepatitis C care presented in this review 
 Nurse-led  
 Telemedicine 
 Multidisciplinary (including non-medical personnel in the core team, e.g. social workers, 
case managers or psychologists) 
 Pharmacist-led 
 Mobile van units 
The models of HCV care were selected by reviewing the peer-reviewed literature in 
PubMed/Medline since 2014, references from relevant articles, and abstracts from the The Liver 
Meeting of the American Association for the Study of Liver Diseases (AASLD 2018); European 
Association for the Study of the Liver International Liver Congress (EASL ILC 2018 and 2019), and the 
International Network on Hepatitis in Substance Users (2018) by three independent researchers (CP, 
JC, EMR), who identified 71 studies that reported studies of new models of care to address HCV that 
had measurable outcomes. Table 1 presents selected case studies by country and population 
addressed, Table 2 highlights the main populations addressed, Table 3 describes setting, and Table 4 
categorizes the provider type.  Fig. 1 presents the stages of the cascade of care addressed 
(awareness and prevention, testing and diagnosis, linkage to care, access to medicine, and patient 
monitoring and evaluation) while Supplementary Table 1 summarizes measurable outcomes, 
including SVR where available. The search words were: 
 PubMed search string (HCV[All Fields] OR ("hepatitis c"[MeSH Terms] OR "hepatitis c"[All 
Fields] OR "hepacivirus"[MeSH Terms] OR "hepacivirus"[All Fields])) AND model[All Fields] 
AND s[All Fields] AND care[All Fields] 












This article is protected by copyright. All rights reserved. 
 
 
One of the hallmarks of a good MoC is simplicity. Simplicity is key to the scaling up of interventions 
and widely considered a predictor of its success. [18-21] Fortunately, because DAAs have few side-
effects and can be administered orally, MoCs designed to optimise DAA delivery are much simpler 
than those designed for pegylated interferon treatment, which required more pre-treatment 
diagnostic procedures (e.g pre-treatment liver biopsy, HCV genotyping) to exclude other causes of 
liver disease, as well as intensive monitoring and dose modification. Other elements that contribute 
to simplicity include effective linkage to care and the targeting and integration (e.g. co-location) of 
services. [22] 
Targeting is also essential. It begins with a concerted effort to test members of hard-to-reach at-risk 
populations, using outreach to come in contact with them where they are, instead of waiting for 
them to present at healthcare facilities. Table 2 presents the seven main populations addressed by 
MoC studies from the DAA era. Of the 71 studies that we reviewed for this paper, 42 targeted PWID. 
Among PWID and other vulnerable populations, rapid testing has been shown to substantially 
increase coverage and referral rates. [23-25] To date, many services have not been developed for 
vulnerable populations such as the homeless, PWID and prisoners, which must both contend with 
numerous social determinants [26-29] that contribute to poor quality of life and poor social 
functioning [30-31] as well as health inequalities. [32] It should be emphasised that HCV treatment 
should be offered based on clinical rather than social factors or injecting-related behaviours,[33-34] 
underlining the necessity of overcoming obstacles to HCV treatment delivery to PWID. In particular, 
several studies demonstrate that HCV treatment achieves acceptable outcomes in active injectors, 
and outcomes that are just as good in people on OST as in people who do not inject drugs. [35-37] 
An enabling policy environment is paramount, [38] since restrictive drug policies and the 












Figure 1. Summary of articles included (n=71) classified by the 
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discourage PWID from accessing both HCV services and drug treatment services, [40] while harm 
reduction services can offer HCV testing that many PWID would otherwise not access. At the same 
time, the daily support typically provided to OST clients on HCV treatment might also prove 
beneficial to other vulnerable individuals receiving treatment. 
Perhaps the biggest obstacle to the scale-up of HCV services in many settings is affordability and 
availability, for both diagnostic tools and treatment. While the right to health suggests that anyone 
infected with HCV should have access to treatment, irrespective of disease stage and drug use, [41] 
some people must pay for them out of pocket in those countries where high costs and/or 
discrimination have led to reimbursement restrictions. Most countries that subsidise DAA therapy 
have restricted access in terms of who can prescribe and disease severity, [3] despite evidence that 
treatment is cost-effective when the long-term costs of morbidity, mortality and onward 
transmission are included in the calculations, and provided that harm reduction is widely available. 
[35, 42-47] Strategies that have proven successful in bringing DAA costs down to a fraction of the list 
price include directly negotiating with pharmaceutical companies, licensing generics and committing 
to scaling up treatment in order to secure bulk discounts and achieve economies of scale.[48] 
Other obstacles also need to be overcome to scale up HCV treatment. [49-50] They include the 
heterogeneity of national policies,[51-53] a lack of appropriate infrastructure for HCV services in 
tertiary centres and addiction clinics, [17, 54-57] stigma and discrimination [58-59] (including the 
reluctance of some physicians to treat PWID [60-62], limited access to point of care diagnostics [63], 
and inadequate knowledge of HCV and HCV treatment and a generally deficient sense of urgency. 
[64-66]  
Two other essential characteristics of successful MoCs that Bruggmann and Litwin emphasised in 
their MoC study, [17] a multidisciplinary approach and integration of services, are addressed below 
in the sections responding to the questions of who and how, respectively.  
Where 
The delivery of HCV services and interventions varies tremendously in practice. Table 3 identifies the 
diverse settings where they can be offered. This section and the next draw on the scientific literature 
for recent experiences in implementing MoCs for HCV, especially among PWID, to explore the 
questions of where, what, who and how. 
Because MoCs are setting-dependent, we have devoted particular attention to the question of 
where. The rest of this section is devoted to the different settings that can provide the primary 
venue for HCV services. While a “one-stop shop” may be ideal, in that it provides continuity, it can 
be difficult to arrange financing for an integrated clinic offering a variety of health and social services 
in a system where funding comes from narrowly defined budgets. Moreover, clients often access 
services according to convenience, and providing services at a variety of sites may offer welcome 
flexibility. In such cases, it is critical to coordinate service provision so that clients receive consistent, 
seamless care regardless of location. 
Where to provide the services: hospitals. For decades, hepatitis C has been managed as a rule by 
specialists in hospitals.[17, 39] As evidence became available on the effectiveness of HCV treatment 










This article is protected by copyright. All rights reserved. 
interferon-based treatment for PWID [67] found satisfactory results in the six studies analysing SVR 
and in the five analysing reinfection.[68-70] While there appeared to be no clear advantage in 
providing treatment to PWID in hospitals instead of community-based settings, [67] most of the 
studies comparing HCV treatment in tertiary/specialist settings with community settings in another 
systematic review showed generally better uptake in the latter. [71] The main challenge is thus 
simplifying care at integrated centres and limiting the hospital role in HCV treatment. While hospital 
specialists may continue to play a key role in integrated HCV care for marginalised populations, 
hospital referrals should ideally be necessary only in cases with severe complications, such as 
advanced liver disease and certain co-morbidities (which are expected to become much less 
common as DAA therapy becomes more widespread). First, however, restrictions on DAA treatment 
in nonhospital settings [72] must be lifted to make such a shift possible. 
Primary care facilities. The feasibility of successfully treating PWID receiving OST with interferon-
based regimens has been broadly demonstrated in studies where well-trained general practitioners 
work with nurses, social workers and other professionals in a primary care setting.[73-75] This model 
can also benefit from telehealth technology.[76]  
The experience of Kirketon Road Clinic [77] in Sydney sheds light on the benefits of delivering DAA 
therapy in primary care (Table 1, Case 1). Among 242 marginalised PWID who started DAA therapy, 
overall 68% achieved SVR by week 12 and only 2 documented virological failures were observed, per 
protocol SVR12 was therefore 99%, with the remainder not attending for an SVR12 test. Seventy-
nine of these people received enhanced support in the form of daily or weekly administration of 
DAAs. Homelessness was associated with requiring enhanced support, but reassuringly this 
approach ensured that virological outcomes and adherence were high. Further research is 
warranted on the impact of housing services on long-term outcomes for PWID.[78-79] 
Multidisciplinary primary care facilities in the United States that provide training and support to 
professional staff have been found to provide high-quality assessment and treatment of PWID with 
HCV,[80-82] but they are not yet common. [83] It is unclear if shifting from an MoC relying on 
infectious disease doctors working in primary care settings to an integrated-care pathway led by 
general practitioners or nurse-practitioners can be both effective and cost-effective. General 
practitioners are still prohibited from prescribing DAAs in most countries, [3] or are limited to 
delegated prescribing, but in countries where they may prescribe freely, such as Australia, the 
proportion of DAAs they prescribe is high.[84] 
Community health centres. These community-based facilities are not fully integrated into the 
healthcare system. The term is used here for centres whose primary focus is not drug addiction. 
There are several examples of community health centre MoCs from the interferon era [71]. In 2001–
2005, the overall SVR for a Canadian treatment cohort, most of them PWID, was 61%, which was 
comparable to outcomes from contemporaneous randomised controlled trials.[85] 
In one systematic review of community-based HCV treatment, most studies were undertaken at OST 
facilities, but none assessed DAA delivery in the community setting.[71] Studies in Toronto [86] and 
Philadelphia [87] (Table 1, Cases 2 and 3) provide evidence of the effectiveness of community-based 
MoCs involving OST and DAAs, and a project in Brighton shows promising preliminary results. [88] A 
Melbourne trial is comparing a control group treated with DAAs and followed at the tertiary level 
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Addiction centres and harm reduction centres. Addiction centres include drug addiction treatment 
centres, primary addiction care units and facilities providing services to help PWID cope with medical 
and psychological issues related to addiction. Harm reduction centres  include OST facilities, NSPs 
and supervised injecting centres; many incorporate peer-based services with medical support. 
A Danish project has provided important evidence of DAA therapy being used in addiction centres 
affiliated with hospital infectious disease departments. Preliminary results show that PWID can be 
tested and treated outside of hospitals, using specialists who prescribe DAAs without ever seeing the 
patient in person (Table 1, Case 4). [90] In an East London study, 83 of the PWID attending an 
outreach clinic, where a consultant hepatologist and a nurse reviewed client cases, expressed 
interest in receiving antiviral therapy, and 58 completed treatment. Compliance was greater than 
80%; homelessness, active drug injection and pre-treatment antidepressant therapy were not 
associated with noncompliance. [91]  
In an Australian multicentre initiative known as ETHOS, 24% of 415 PWID were treated with 
interferon-based regimes; of them, 62% were receiving OST. Among the treated PWID, adherence 
was 86% and SVR 74%.[92] Studies of OST cohorts in Norway [93] and Ireland [37] show similarly 
encouraging results. Such figures are expected to improve even more as the use of DAAs becomes 
universal. 
Scant data are available from recent studies using DAAs in OST settings, [94] though an international 
trial from 2016 concluded that drug use ought not to be a barrier to DAA therapy in patients 
receiving opioid agonist therapy. [95] Further, acceptability and feasibility of dosing DAAs through an 
OST infrastructure has been demonstrated. [96]  
NSPs too have been shown to be effective and cost-effective in preventing both HIV [97] and HCV 
transmission among PWID. [98-99] They are essential for optimising linkage to care and testing, 
especially among young PWID,[100] and can also serve as a venue for HCV treatment. A large 
Australian study of PWID attending NSPs in 1999–2011 found that the proportion treated for HCV 
increased over time, although overall numbers never exceeded 10%. [101]  
There is also evidence for the effectiveness of supervised injecting centres in preventing HCV and 
other blood-borne infections and avoiding other serious medical complications. [102-103] 
Assessment for liver disease has proven suitable in this setting. [104-105] However, beyond a survey 
of hepatitis C services offered at supervised injecting centres globally, [106] we found no studies 
assessing implementation of HCV treatment pathways through such centres. Moreover, models 
involving these centres, such as the “service model” used by the European Monitoring Centre for 
Drugs and Drug Addiction, rarely address HCV.[107] Basic work is thus still needed to conceptualise 
the role of supervised injecting centres within the HCV cascade. 
Prisons. PWID, both former and current, form a large proportion of the prison population. [108] A 
study involving 3126 HCV-infected individuals incarcerated in the United States showed that rates of 
linkage to care and treatment for adults were very low, with just 18% being evaluated for initiation 
of treatment while incarcerated, and a mere 10% initiating DAAs. [109] The high burden of HCV 
infection in prisons, together with the presence of other conditions such as HIV infection, HBV 
infection or drug use, creates a syndemic cluster that is difficult to address. On the other hand, 
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therapeutic strategies. For instance, a recent modelling study concluded that incarceration 
contributes a 28% risk of HCV transmission among PWID in Scotland, but scaling up HCV treatment 
to 80% of chronically infected PWID with sufficiently long sentences (>16 weeks) upon entrance to 
prison was able to reduce both the incidence and prevalence of HCV by 46%.[110] Offering prisoners 
HCV services upon intake is quite rare, however. Another recent study using a prevention benefit 
analysis concluded that increasing HCV testing in United Kingdom prisons is marginally cost-effective 
compared to current voluntary risk-based testing, but it could be highly cost-effective if DAAs are 
broadly prescribed and PWID treatment rates increased.[111] A similar United States study drew 
similar conclusions. [112] Other authors have demonstrated that scaling up harm reduction services 
is a prerequisite to effectively tackling HCV, HIV and drug epidemics in prisons.[113] Another 
challenge is ensuring prisoners uninterrupted treatment upon release. One study offered prisoners 
who began DAA therapy while in prison but who were released early with their remaining 
medication to complete treatment in the community. [114] This same study also offered short 
sentence duration prisoners ineligible for treatment referrals to healthcare services for treatment in 
the community once released.  
A systematic review of the effectiveness of MoCs for HCV in European prisons found that seven 
studies utilising second-generation DAAs in France, Italy and Spain achieved SVR rates of 85% to 
98%, and one study that switched from interferon therapy to DAA therapy increased SVR rates from 
62%–68% to 90%–98%. [115] A Spanish study demonstrated that HCV elimination is possible in a 
prison setting. Using a test-and-treat strategy, the prison tested 99.5% of its inmates, treated all who 
were infected and would be incarcerated more than 30 days, established a teleconsultation 
programme for those who were released, and achieved SVR in 97% of the treated prisoners (Table 1, 
Case 5). [116] 
Pharmacies. Available evidence supports including pharmacies as essential service venues in MoCs 
for treating HCV in PWID (Table 1, Case 6). [36,117] Some pharmacies dispense OST and thus have 
daily contact with people on OST, and some also offer needle and syringe services. One study 
demonstrated the feasibility of implementing DAAs through a community pharmacy for PWID 
receiving OST. [36]  
In addition, both rapid testing using dried blood spots [118] and syringe distribution [119] have been 
proven effective in community pharmacies. These findings suggest that any further development of 
MoC designs and policies to incorporate HCV services for PWID at pharmacies should be based on 
the use of standard community pharmacies rather than hospital or specialist pharmacies, which can 
pose barriers to PWID access. 
Sexual health clinics. Sexual health clinics provide a good platform for linkage to the HCV cascade. 
Australian and United Kingdom studies have demonstrated that interferon-based treatment in 
sexual health clinics, including follow-up and regular assessments, resulted in SVRs comparable to 
treatment at specialist clinics. [120-122] However, we were unable to identify any studies assessing 
rapid point-of-care testing followed by DAA therapy in this setting. Other studies from Australia and 
the United Kingdom linking confirmed HCV infections in sexual health clinics to injecting drug use 
have shown that HCV and HIV screening is feasible there but probably insufficient. [1423-124] It has 
not yet been determined whether HCV screening in this setting should be clinician-led, as with these 
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should be implemented there instead. Guidelines on who to test for hepatitis C in sexual health 
services are available, and often risk-factor based [125]. In either case, in order to achieve 
elimination in high-risk populations such as men who have sex with men, primary prevention and 
the prevention of reinfection will play a major role. [126-128] 
What, who, and how 
What services to provide. It is well worth consulting the latest HCV guidelines from WHO, [129-130] 
the European Association for the Study of the Liver (EASL), [34] the American Association for the 
Study of Liver Diseases (AASLD), [131-132] and the International Network on Hepatitis in Substance 
Users [133]. These guidelines all include concrete recommendations for providing HCV services to 
marginalised populations, and the WHO guidelines specifically address the needs of low- and middle-
income countries. In addition, several systematic reviews helpfully provide an overview of the 
evidence for various interventions for PWID in the DAA era.[23-24, 134-135] 
Simplicity, scalability and patient convenience should be the bywords in developing an MoC. They 
call for a test-and-treat model wherever possible, to eliminate the gaps between testing and 
treatment.[136-143] Strong referral links in all directions between testing, treatment, harm 
reduction and social services are of paramount importance. In countries with high diagnosis rates, 
attention should be paid to reengaging PWID who have been diagnosed in the past and getting them 
into care. For a high-prevalence population like PWID, rapid antigen or RNA testing is appropriate, 
the latter providing results within an hour, [137, 144-145] and it may be sensible to omit genotyping 
if there is no major price differential between pangenotypic DAAs and genotype-specific ones. If 
transient elastography is not readily available, it may make sense to skip or postpone it too, or use 
alternative easily available fibrosis assessment tools such as APRI [146]. Table 4 summarises the 
findings from the literature search organised by the stages in the cascade of care. 
DAA therapy is now the treatment of choice for all patients and everything should be done to ensure 
its availability. [35, 147] Access to harm reduction services are critical, as discussed above, to reach 
key, high-burden populations. Finally, good patient follow-up and contact are essential to help 
ensure adherence and maximise cure rates. Appropriate peer support, as discussed in the next 
section, can be crucial in increasing service uptake and retention, particularly in working with 
marginalised populations. 
Who to provide the services. Throughout the HCV cascade of care, multidisciplinary teams of 
healthcare and social service professionals can help ensure the best possible outcomes, which in 
turn will improve public health. That is why the International Network on Hepatitis in Substance 
Users recommends treating HCV in a multidisciplinary team setting. [148] Multidisciplinary 
approaches encompassing biomedical, psychoeducational and social interventions have been shown 
to improve engagement in care, [149] treatment uptake, [149-151] patient adherence and retention, 
[152-157] management of HCV/HIV coinfection [158] and of HCV in psychiatric patients,[159] stigma 
reduction and patient well-being,[28, 87] and reduction in mortality.[141] However, the creation of 
multidisciplinary teams or structures where existing structures are functioning effectively is not a 
requirement of a good MoC. 
As mentioned above, in moving from MoCs designed around interferon-based treatment to MoCs 
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With DAA therapy, HCV assessment and treatment no longer require specialist training, so it makes 
sense to expand who may assess HCV infection and prescribe treatment beyond specialists in 
tertiary care centres. With proper training, anyone can undertake assessment and prescribe DAAs 
competently, either as a delegated prescriber or a nonmedical prescriber – which again facilitates 
scale-up. Evidence has shown good results from the prescribing of DAAs by primary care providers, 
drug and alcohol service providers, nurse-practitioners, nurses, including nurse prescribers, and 
pharmacists.[160-163] Delegated prescribing may be a good option where prescribing is limited by 
statute. Table 5 presents the diversity of providers featured in the 71 recent MoC studies reviewed 
for this paper, including 18 studies highlighting the benefits of multidisciplinary teams. 
Particularly when using non-specialist service providers, it is essential to invest in human resources, 
hiring the best people for the job and providing them with thorough and regular training. One model 
that has proven useful in helping such providers serve vulnerable and dispersed populations is the 
model promoted by Project ECHO (Extension for Community Healthcare Outcomes).[164] By 
engaging frontline service providers with a continuous learning system and specialist mentors, it can 
dramatically increase the access of PWID to HCV care and treatment. [165-166] 
A peer provider can use shared experience, as someone who has had chronic hepatitis C and/or 
someone who has been part of a target population, to connect with vulnerable people and help 
them through the cascade of care. They can also use their experience to help ensure that MoCs 
reflect client concerns. Limited data from both the interferon era [167] and the DAA era highlight 
[168-169] the potential benefit of including peer support workers in MoCs.  
Countries with very broad community access to DAAs, such as Australia, [170] have been successful 
in mobilizing the peer workforce and training them to provide services at different points in the 
cascade of care, where they have been crucial in building momentum towards HCV elimination. 
How to integrate services. In the DAA era, as mentioned above, the ideal form for a successful MoC 
for PWID with HCV is either a one-stop-shop approach, in which all relevant services are integrated 
in locations where people are already accessing other services, or a flexible approach, in which 
various sites and services are well coordinated and strongly linked. The challenge in implementing 
the one-stop approach is to evolve towards comprehensive yet decentralised points of care, [171] 
for instance through single-visit diagnoses.[137] Multidisciplinarity and integration go hand in hand, 
yet it is important to emphasise two necessary features of the integration process in developing a 
robust MoC for marginalised populations. First, integration should take place within systems where 
these populations already access services, particularly OST and NSPs in the case of PWID. [172] The 
aim should be to bring services closer to the client, rather than expecting the client to seek them 
out. And second, it requires training that is also multidisciplinary and integrated, which will include 
task-shifting, so that fewer kinds of professionals are providing more services in the same settings, 
thereby necessitating fewer visits to access them. 
In their seminal review on MoCs for HCV, Bruggmann and Litwin contrast various integrated MoCs 
with conventional secondary and tertiary care models. [17] Where it is feasible and affordable, we 
advocate integration: delivering integrated care in non-specialist settings that are better suited to 
the care of vulnerable individuals. In Scotland, where managed care networks exemplify integrated 
multiagency MoCs, they have been shown to improve not only HCV outcomes, but also outcomes 
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Although not exhaustive, we have presented many examples demonstrating that integrated MoCs 
are effective in addressing the entire HCV cascade of care (Fig. 1), plus evidence that an integrated 
format might be particularly well suited to primary care, community health centres, addiction and 
harm reduction centres, prisons, sexual health clinics, pharmacies and other settings. Such models of 
care can target both the typical young drug user and the veteran of addiction treatment, [175-176] 
for instance, thereby increasing overall eligibility for HCV treatment [177] while providing for 
appropriate counselling, peer support [149] and management of medical, mental health and social 
issues for both those on opioid substitution therapy and those who are not.[75, 88, 178-179] 
Conclusion 
Around the world, models of care for HCV need to be redesigned to reflect the recent availability of 
DAAs if countries are to meet their commitments to eliminating HCV as a public health threat by 
2030, as set out by WHO. In some countries, this will require major changes to established care 
pathways and systems. One immediate challenge for policymakers and researchers is to develop 
cost-effective, easily implemented mechanisms that incorporate health information and 
reimbursement systems, and interdisciplinary and multifacility communication. Healthcare 
providers, affected populations and other key stakeholders should be involved in such development 
to ensure that the final mechanisms represent relevant perspectives and are mutually beneficial to 
all. While further research on the feasibility of different MoCs in specific settings is needed, much 
can be learned from examining the innovative MoCs reviewed here, which suggest that an effective 
model of care for HCV infection should be simple, targeted, multidisciplinary, scalable, integrated, 
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Table 1. Models of Care for Hepatitis C in People who Inject Drugs – some representative cases 
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How (integration approach) Findings 















Viral hepatitis testing, 
DAA therapy, hepatitis A 
and B vaccination, 
“healthy liver clinic” with 
specialized hepatitis 
service; sexual health 





social service and 
welfare assistance; 
methadone access and 
case management; NSP; 
street van and bus 







Integrated primary health care model 
offering anonymous services to risk 
populations. DAAs can be provided 
through a community pharmacy, with 
a follow-up phone call to confirm 
treatment initiation, standard of care 
pathology. Enhanced adherence 
support includes phone calls or other 
contact at least weekly, flexible 
directly observed dispensing of the 
medications, with or without OST, 
linkage to partner organisations, DAA 
delivery to prisons, police cells, 
psychiatric units and general hospital 
wards. 
242 PWID were included, 74% recent or 
current injectors, 44% enrolled in OST. 79 
(32%) of clients chose enhanced daily or 
weekly dosing support options. Enhanced 
support was associated with homelessness, 
daily injecting, Aboriginality, mental health 
co-morbidity and poly-drug use (all 
p<0.001). Overall adherence was 86%, and 
92% of patients missed one or more doses 
(median 10, IQR 4-24). The study confirms 
that PWID can be successfully treated for 
HCV in a real-world setting using an 
integrated primary health care model and 
demonstrates the feasibility of scaling DAA 
therapy up in high-risk PWID populations. 









DAA therapy, weekly 




Integrated multidisciplinary specialist 
support on site 
74 PWID initiated DAA therapy, achieving 
high adherence and SVR with appropriate 
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in a medically 
underserved 
neighbourhood 
with high rates 
of HCV and HIV 
Social marketing 
campaign, door-to-door 
outreach, rapid HIV and 
HCV screening in a 
mobile medical unit, 
immediate phlebotomy 
for confirmatory testing 
of reactive antibody 
tests, facilitation of client 
enrolment in health 
insurance, linkage to care 















Developed and coordinated a local 
hospital and local university 
Among 1301 people screened, 2.8% were 
chronically infected, half of whom were 
newly diagnosed. The biggest barrier to 
retention in care was obtaining referrals 
for subspecialty providers due to a lack of 
insurance. Some subjects started treatment, 
while many who were eligible were 
awaiting approval from insurance 
companies. This study illustrates how a 





 Linnet et 
12 drug 
counselling 
Hepatitis and HIV 
counselling and testing; 
GPs, hospital 
specialists, 
Decentralised shared care model, in 
which hospital infectious disease 
More than 700 people were screened for 
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various drug and alcohol 




department was responsible for 
prescription and monitoring the 
course of treatment, while the drug 
treatment staff were responsible for 
testing, assessment, dispensing and 
adherence support 
clients tested for HCV in the treatment 
centres increased by 50%, and 208 were 
diagnosed with chronic HCV infection; 25 of 
them ended up being treated and cured. 
The model permitted many more people to 
be diagnosed and cured than otherwise, 
despite little tradition of collaboration 
between the centres and the hospital. 
5. Cuadrad










HBV, HCV and HIV 
screening and diagnosis; 
DAA therapy, 
teleconsultation; 
phylogenetic analysis of 
nonresponders, followed 




















A video collaboration tool was used 
for consultations between prison and 
hospital teams, as well as between 
treatment recipients and a hospital 
hepatologist, also after any inmate 
release. Treatment was prescribed by 
the hepatologist and administered by 
the prison healthcare providers. 
Prisoners were consulted on study 
design, and their input contributed to 
the use of telemedicine and the choice 
of the quickest treatment regiment 
(non-ribavirin). 
A test-and-treat strategy enabled the prison 
to screen 99.5% of its inmates for HCV, 
treated everyone who was infected and 
would be in prison more than 30 days, 
established a teleconsultation programme 
for those who were released. The 
programme achieved SVR in 97% of the 
treated prisoners. At the end of the 
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Dried blood spot testing, 
OST, DAA therapy 
Pharmacists, 
physicians 
Community pharmacies referring 
patients who test positive for HCV to 
clinics for assessment and treatment 
HCV testing and treatment is feasible in 
community pharmacies, especially for 
patients already  receiving OST there. 
Compared to nurse-practitioners, 
pharmacists were much more likely to get 
patients to take a rapid HCV test, and for 
clients with reactive tests, the pharmacist 
were much more successful in getting them 
to attend a clinic for assessment and 
treatment. 

















and substance misuse 
counseling/ social 
support (provided by 
primary care 
physician) and HCV 
treatment. A 
specialist registrar 





One stop HCV clinic at two major 
homeless hostels in Southeast 
England. 
72 attended the clinic, 71 (99%) were 
included in the program, 28 (39,4%) 
were anti-HCV positive, 26/28 
consented to further testing, 20/26 
were HCV RNA positive, 5/20 started 
DAA treatment. Results in 2019: 131 
individuals approached, 127/131 
individuals enrolled in the program, 
59/127 were HCV Ab positive, 48/59 
were HCV RNA posiitve, 28/48 
initiated HCV treatment, 14/17 
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the supervision of a 
Hepatologist. 
treatment/waiting SVR results, 1 
discontinued the treatment. 










liver fibrosis assessment, 
complete laboratory 
work, treatment 
initiation with DAAs 
Multidisciplin
ary 
Awareness raising campaign 
followed by HCV screening by 
using HCV antibody RDT a week 
later. Anti-HCV positive got 
tested for HCV RNA with 
GeneXpert IV, and on the same 
day the HCV RNA positive 
patients had the Fibroscan, 
abdominal ultrasound and basic 
laboratory work (liver function, 
renal function, CBC, AFP) and 
initiated treatment with DAA. 
475 individuals were screened for 
anti-HCV antibodies by RDT, 56 had 
PCR HCV RNA, 43 positive for HCV 
RNA, 40 initiated the treatment, 3 
were excluded due to focal hepatic 
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Table 2. Populations addressed in the models of care selected  
Population (n) Country N. of study (from Supplementary material 1) 
PWUD*/ on OST 
(42/3) 
Australia; Belgium; Canada; 
Denmark; France; Georgia; 
Greece; Ireland; Norway; 
Portugal; Spain; Switzerland; 
UK; USA 
Papaluca T et al. (1), Alimohammadi A et al. (2), Remy AJ et al. (3), Bourgeois S et al. (4), 
Chronister KJ et al. (6), Valencia JA et al. (7), Liberal R et al. (8),  Inglis SK et al. (10), Ford MM et 
al. (11), Borojevic M et al. (12), Peters L. (13), Williams B et al. (14), Saludes V et al. (15), O’Loan J 
et al. (16), Grebely J et al. (17), Norton et al. (30), Morris et al. (31), Schulkind J et al. (33), Saludes 
V et al. (34), Radley A et al. (35), Alam Z et al. (37), Sypsa V et al. (40), Kugelmas M et al. (42), 
Howell et al. (43), Kraichette N et al. (44), Greenan S et al. (45), Ryder N et al. (46), Doyle J et al. 
(47),  Bielen R et al. (48), Stvilia K et al. (49), Mitchell S et al. (50), Thompson H et al. (51), 
Lamond S et al. (53), Sinan F et al. (54),Midgard H et al. (56), Berger SN et al. (57), Read P et al 
(60), Mason K et al (62), Hashim A et al (63), Treloar C et al (64), Chronister KJ et al (65), Linnet 
et al (65),  Barror S et al. (66),  Simoes D et al. (68),  Nouch S et al (69),  Scherer ML et al. (71) 
Specifically OST: Inglis SK et al. (10), Radley A et al. (35), Bielen R et al. (48) 
General population 
(20) 
Australia; Canada, Egypt; 
India; Mexico; Pakistan; USA 
Balcomb A (5), Ford MM et al. (11), Trooskin et al. (18), Chiong F et al. (23), Cooper et al. (24), 
Capileno et al. (25), El-Akel et al. (26), Kattakuzhy et al. (29), Dhiman RK et al. (36), Shiha G et al.  
(38), Shiha G et al. (39), Greenan S et al. (45), Ryder N et al. (46), Thompson H et al. (51), Perez 
Hernandez JL et al. (52), Lamond S et al. (53), Naveed A et al. (55), Koren D et al. (59), Sokol et al 
(61), Nouch S et al (69) 
Prisoners 
(11) 
Australia; France; Ireland; 
Portugal; Romania; Spain; 
Sweden; UK 
Papaluca T et al. (1), Remy AJ et al. (3), Liberal R et al (8), Cuadrado A et al (9), Inglis SK et al. 
(10), Vroling H et al. (20), Olsson A et al. (21), Bartlett SR et al. (22), Overton et al. (41), Barror S 




Australia; Canada, France; 
Romania; Scotland; Spain; 
UK 
Alimohammadi A et al. (2), Remy AJ et al. (3),  O’Loan J et al. (16), Grebely J et al. (17),  Hashim A 
et al. (28),  Macbeth K et al. (32),  Barror S et al. (66) 
Sex workers 
(5) 
Australia; Ireland; Italy; 
Romania; Spain; Portugal; 
UK 
Chronister KJ et al. (6), Read P et al. (60),  Barror S et al. (66),  Teti E et at. (67), Simoes D et al. 
(68) 
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(3) 
People with mental health 
issues 
(2) 
Canada, France Mason K et al (62), Remy AJ et al. (2) 
Other (reviews) 
(2) 
Multi-country reviews Pourmarzi et al. (19), Wade et al. (27) 
Veterans 
(1) 




Simoes D et al. (68) 
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Table 3. Setting in the models of care selected 
Setting (n) Country N. of study (from Supplementary material 1) 
Low-threshold setting 
(25) 
Australia; Belgium; Canada; 
Denmark; France; Georgia; Greece; 
Italy; Ireland; Norway; Portugal; 
Romania; Spain; UK; USA 
Alimohammadi A et al. (2), Remy AJ et al. (3), Bourgeois S et al (4), Valencia JA et al. (7), 
Ford MM et al. (11), Williams B et al. (14), Saludes V et al (15), O’Loan J et al. (16), Grebely J 
et al. (17), Hashim A et al. (28), Morris et al. (31), Schulkind J et al. (33), Saludes V et al. 
(34), Sypsa V et al. (40), Howell et al. (43), Stvilia K et al. (49), Mitchell S et al. (50), Sinan F 
et al. (54), Midgard H et al. (56), Treloar C et al (64), Chronister KJ et al (65), Linnet et al 
(65), Barror S et al. (66), Teti E et al. (67), Simoes D et al. (69), Scherer ML et al. (72) 
Primary care 
(20) 
Australia, Canada, Ireland, Mexico, 
Pakistan, Romania, Scotland, Spain, 
UK, USA 
Balcomb A (5), Chronister KJ et al. (6), Trooskin et al. (18) Capileno et al.(25), Kattakuzhy 
et al.(29), Norton et al. (30), Macbeth K et al. (32), Doyle J et al. (47), Thompson H et al. 
(51), Perez Hernandez JL et al. (52), Lamond S et al. (53), Naveed A et al. (55), Koren D et 
al. (59), Read P et al (60), Sokol et al (61), Mason K et al (62), Hashim A et al (63), Treloar C 
et al (64), Chronister KJ et al (65), Barror S et al. (66), Nouch S et al. (69) 
Prison 
(9) 
Australia, Ireland, Romania, Spain, 
Sweden, Portugal, UK 
Papaluca T et al. (1), Liberal R et al (8), Cuadrado A et al (9), Vroling H et al. (20), Olsson A 




Belgium, Denmark, Switzerland, USA 
Borojevic M et al (12), Peters L. (13),  Alam Z et al. (37), Kugelmas M et al. (42), Bielen R et 
al. (48), Berger SN et al. (57) 
Hospital 
(4) 
Australia, Canada, India Chiong F et al. (23), Cooper et al. (24), Dhiman RK et al. (36), Ryder N et al. (46) 
Rural 
(4) 
Canada, Egypt, France 
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Pharmacy 
(3) 
Scotland, USA Radley A et al. (35), Fleming BS et al. (58), Koren D et al. (59) 
Mobile van 
(4) 
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Table 4. Providers in the models of care selected 
Providers (n) Country N. of study (from Supplementary material 1) 
Multidisciplinary* 
(22) 
Australia; Canada; Denmark; Egypt; 
France; Greece; Ireland; Portugal; 
Romania; Spain; Switzerland; UK; 
USA 
Alimohammadi A et al. (2) Remy et al. (3), Balcomb A (5), Chronister KJ et al. (6), Valencia 
JA et al. (7), Cuadrado A et al (9), Inglis SK et al. (10), Ford MM et al. (11), Borojevic M et al 
(12), Peters L. (13), Trooskin S et al. (18), El-Akel et al. (26), Morris et al. (31), Macbeth K 
et al. (32), Shiha G et al. (39), Sypsa V et al. (40), Fleming BS et al. (58), Mason K et al (62), 
Chronister KJ et al (64), Linnet et al (66), Barror S et al. (66), Simoes D et al. (68) 
Medical specialists^ 
(26) 
Australia; Belgium; Canada; France; 
India; Norway; Pakistan; Portugal; 
Sweden; UK; USA 
 
Papaluca T et al. (1), Alimohammadi A et al. (2), Bourgeois S et al (4), Liberal R et al (8), 
Williams B et al. (14), Olsson A et al. (21), Bartlett SR et al. (22), Chiong F et al. (23), 
Hashim A et al. (28), Kattakuzhy et al. (29), Norton et al. (30), Dhiman RK et al. (36), Alam 
Z et al. (37), Overton et al. (41), Kraichette N et al. (44), Greenan S et al. (45), Ryder N et 
al. (46), Mitchell S et al. (50), Thompson H et al. (51), Lamond S et al. (53), Midgard H et 
al. (56), Berger SN et al. (57), Sokol et al (61), Hashim A et al (63), McDonald L et al. (70), 
Scherer ML et al. (71) 
General practitioners 
(12) 
Australia; Belgium; Canada; France; 
India; Norway; Pakistan; Portugal; 
Sweden; UK; USA 
O’Loan J et al. (16), Chiong F et al. (23), Hashim A et al. (28), Kattakuzhy et al. (29), 
Thompson H et al. (51), Perez Hernandez JL et al. (52), Lamond S et al. (53), Naveed A et 
al. (55)*, Sokol et al (61), Mason K et al (62), Barror S et al. (66), Nouch S et al. (69) 
*Defined in manuscript as “doctors without speciality training” 
Telemedicine 
(7) 
Australia; Spain; Canada; Mexico; 
USA 
Balcomb A (5), Cuadrado A et al (9), Vroling H et al. (20), Olsson A et al. (21), Cooper et al. 
(24), Perez Hernandez JL et al. (52), Komaromy M et al (67) 
Nurse-led 
(14) 
Australia; Belgium; Canada; 
Georgia; Sweden; UK; USA 
 
Papaluca T et al. (1), Williams B et al. (14), Vroling H et al. (20), Olsson A et al. (21), 
Kattakuzhy et al. (29), Schulkind J et al. (33), Doyle J et al. (47), Bielen R et al. (48), Stvilia 
K et al. (49), Mitchell S et al. (50), Sinan F et al. (54), Berger SN et al. (57), Hashim A et al 
(63),McDonald L et al. (70) 
Specialist nurse (but not nurse-
led) 
(12) 
Australia; Belgium; Canada; 
Norway; UK; USA 
Bourgeois S et al (4), O’Loan J et al. (16), Bartlett SR et al. (22), Chiong F et al. (23), Cooper 
et al. (24), Radley A et al (35), Overton et al. (41), Greenan S et al. (45), Thompson H et al. 
(51), Naveed A et al. (55) Midgard H et al. (56), Fleming BS et al. (58) 
Peer-support 
(3) 
Australia; Belgium Bourgeois S et al (4), Chronister KJ et al (6), Treloar C et al (64) 















Pakistan Capileno et al. (25) 
Not reported/Not specified 
(8) 
Australia; Egypt; Spain; USA 
 
Saludes V et al (15), Grebely J et al. (17), Saludes V et al. 2 (34), Shiha G et al.  (38), 
Kugelmas M et al. (42), Howell et al. (43), Read P et al (60), Teti E et al. (67) 
Other (reviews) 
(3) 
Multi-country reviews Pourmarzi et al. (19), Vroling H et al. (20) Wade et al. (27) 
*A multidisciplinary team was defined as including non-clinical key personnel on the team in addition to clinicians (i.e. social worker, case manager, psychologist, 
etc.) 
^A medical specialist was defined as any medical doctor that had speciality training such as; hepatologists, gastroenterologists, infectious disease specialists, sexual 
health physicians, HCV clinicians) 
 
